ARTICLE | Company News
U of Helsinki grants Herantis rights to a non-invasive CDNF approach
July 20, 2018 5:22 PM UTC
University of Helsinki (Helsinki, Finland) granted Herantis Pharma plc (HSE:HRTIS) exclusive, worldwide rights to a therapeutic approach for non-invasive delivery of cerebral dopamine neurotrophic factor (CDNF) based on a modification of natural CDNF. The partners did not respond to inquiries.
The biotech said it is looking "to broaden the application of CDNF in Parkinson's disease and potentially other neurodegenerative disorders."...
BCIQ Target Profiles